ResMed (RMD) Q1 2025 10-Q Quarterly Report
Filed: Apr 24, 2025Period ending Mar 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR ResMed (RMD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 24, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ResMed Q1 2025 10-Q Analysis
Risk Factors
- • New risk: U.S. tariffs on imports from Canada, Mexico, China triggered retaliatory trade measures impacting sourcing costs and revenue
- • Updated macroeconomic risk: Recent Red Sea shipping disruptions added to inflation, currency, and capital market volatility affecting supply chain and demand
- • Regulatory risk: Potential new international trade laws could increase cost of goods exported, raise effective tax rate, and materially hurt financial condition
- • Operational risk: Supply chain constraints on raw materials and components causing higher costs, minimum purchase obligations, upfront payments, and production delays
- • Market risk: Deteriorating global economy may reduce product demand, lower prices, and reduce reimbursement rates by third-party payors
ResMed Q1 2025 Quarterly FinancialsXBRL
Revenue
$1.3B
▲ +7.9% YoY▲ +0.8% QoQ
Net Income
$365M
▲ +21.5% YoY▲ +5.9% QoQ
Net Margin
28.3%
▲ +316bp YoY▲ +138bp QoQ
Source: XBRL data from ResMed Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other ResMed Quarterly Reports
Get deeper insights on ResMed
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.